Attune Pharmaceuticals is a private biotechnology company focused on discovering and developing novel orally-administered small-molecule therapeutics for the treatment of rare diseases.


May 22, 2017

Attune Pharmaceuticals Announces Positive Data from Recent Pre-Clinical Studies for ATN-249, an Oral Plasma Kallikrein Inhibitor for the Treatment of HAE at C1-INH Deficiency Workshop